Eman Elberri

Eman Elberri


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in Molecules
Verified
Journal Article
Open access
PDF file
HMHend E Abo Mansour
Hend E Abo Mansour
AEAya ibrahim Elberri
Aya ibrahim Elberri
MGMai Ghoneim
Mai Ghoneim
WSWaad Samman
Waad Samman
AAAisha A. Alhaddad
Aisha A. Alhaddad
EMEsraa Mosalam
Esraa Mosalam
Background: Alzheimer’s disease (AD) is a common neurodegenerative disorder without effective treatment. Thymoquinone (TQ) has demonstrated potential in exhibiting anti-inflammatory, anti-cancer, and antioxidant characteristics. Despite TQ’s neuroprotection effect, there is a scarcity of information regarding its application in AD research, and its molecular trajectories remain ambiguous. Thus, the objective of the current investigation was to examine the potential beneficial effects and underlying mechanisms of TQ in scopolamine (SCOP)-induced neuronal injury to mimic AD in vivo model. Methods: Thirty mice were divided into normal, SCOP, and TQ groups. The Y-maze and pole climbing tests were performed to measure memory and motor performance. Afterwards, histopathological and immunohistochemical examinations were carried out. Furthermore, peroxisome proliferator-activated receptor gamma (PPAR-γ) signaling pathway-related proteins and genes were detected with an emphasis on the role of miR-9. Results: TQ has the potential to ameliorate cognitive deficits observed in SCOP-induced AD-like model, as evidenced by the improvement in behavioral outcomes, histopathological changes, modulation of the expression pattern of PPAR-γ downstream targets with a significant decrease in the deposition of amyloid beta (Aβ). Conclusions: TQ provided meaningful multilevel neuroprotection through its anti-inflammatory and its PPAR-γ agonist activity. Consequently, TQ may possess a potential beneficial role against AD development.


1 April 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
KAKhlood Mohammad Aldossary
Khlood Mohammad Aldossary
HTHend Talkhan
Hend Talkhan
FAFurqan M Abdulelah
Furqan M Abdulelah
FKFedaa Kotkata
Fedaa Kotkata
YEYasmine M Elmorsi
Yasmine M Elmorsi
MBMostafa Bahaa
Mostafa Bahaa
Background: Non-alcoholic fatty liver disease (NAFLD) represents a prevalent, long-standing hepatic condition marked by the accumulation of fat in the liver and varying degrees of fibrotic changes. Ketotifen, a mast cell stabilizer, has been proposed to modulate inflammation and fibrogenesis, but clinical evidence is limited. Objective: To assess the effectiveness and safety of ketotifen vs vitamin E in individuals with NAFLD. The primary outcome was the change in hepatic steatosis, while the secondary outcomes included modifications in fibrosis-related indices and inflammatory biomarkers. In addition to other biochemical, anthropometric, and metabolic parameters. Methods: In this randomized study, 60 individuals with NAFLD were allocated in a 1:1 ratio into two groups. The vitamin E group was treated with vitamin E, and the ketotifen group received ketotifen for six months. Anthropometric parameters, liver steatosis and fibrosis, lipid profile, glycemic markers, liver enzymes, matrix metalloproteinase (MMP)-9, and tumor necrosis factor (TNF)-α were measured before and after 6 months. Results: Ketotifen treatment resulted in significant improvements in hepatic steatosis and disease activity compared with vitamin E, including lower steatosis and FibroScan-AST (FAST) score. Fibrosis severity was also reduced, with significant decreases in fibrosis score and fibrosis index (FIB-4) index, whereas Metabolic-Associated Steatosis Combined with Keratin-18 (MACK-3) score showed no significant between-group change. Glycemic outcomes improved significantly with ketotifen, including reductions in HOMA-IR, fasting blood glucose, and fasting insulin. Ketotifen also significantly reduced AST, TNF-α and MMP-9, and improved central adiposity measures (hip circumference, waist–stature ratio. No significant differences were observed for lipid profile, body weight, body mass index, or HbA1c. Ketotifen was generally well tolerated; drowsiness was the most common adverse event. Conclusion: Ketotifen exerts superior hepatoprotective, anti-inflammatory, antifibrotic, and insulin-sensitizing effects compared with vitamin E in NAFLD. These findings suggest that ketotifen may offer a promising adjunctive therapy for NAFLD. Clinical Trial Registration: NCT05616442.

7 May 2026 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
SWSalma S. Wahby
Salma S. Wahby
TMTarek M. Mostafa
Tarek M. Mostafa
MEMohamed A. Alm El-Din
Mohamed A. Alm El-Din
EEEman Elberri
Eman Elberri

17 November 2025 in Molecules
Verified
Journal Article
Open access
PDF file
HMHend E Abo Mansour
Hend E Abo Mansour
AEAya ibrahim Elberri
Aya ibrahim Elberri
MGMai Ghoneim
Mai Ghoneim
WSWaad Samman
Waad Samman
AAAisha A. Alhaddad
Aisha A. Alhaddad
EMEsraa Mosalam
Esraa Mosalam
The journal retracts the article “The Potential Neuroprotective Effect of Thymoquinone on Scopolamine-Induced In Vivo Alzheimer’s Disease-like Condition: Mechanistic Insights”